... who are refractory or resistant to treatment with an erythropoiesis stimulating agent. were down 5.7% to $25.75. The Ardsley, N.Y.-based company reported third-quarter non-GAAP net income of $20.1 million, or $0.43 per diluted share, compared with a ...
http://ift.tt/2hquKcV
No comments:
Post a Comment